Dao Wen Wang

Wuhan Daowen Pharmaceutical Technology is a biotechnology company specializing in the development of gene therapies and small molecule drugs for cardiovascular and metabolic diseases. The company was founded by Dr. Dao-Wen Wang, a leading cardiologist whose research focuses on the protective roles of the CYP2J2 enzyme and soluble epoxide hydrolase (sEH) inhibition. Wuhan Daowen's pipeline features AAV-delivered gene therapies aimed at providing durable treatment for conditions such as chronic heart failure and resistant hypertension. By targeting the arachidonic acid metabolic pathway, the company seeks to develop first-in-class treatments that address the underlying mechanisms of cardiovascular damage. Their work represents a significant effort to translate academic excellence in molecular cardiology into clinical applications.